Abstract
Status epilepticus (SE) prognosis is related to nonmodifiable factors (age, etiology), but the exact role of drug treatment is unclear. This study was undertaken to address the prognostic role of treatment adherence to guidelines (TAG). We prospectively studied over 26 months a cohort of adults with incident SE (excluding postanoxic). TAG was assessed in terms of drug doses (±30 % of recommendations) and medication sequence; its prognostic impact on mortality and return to baseline conditions was adjusted for etiology, SE severity [Status Epilepticus Severity Score (STESS)], and comorbidities. Of 225 patients, 26 (12 %) died and 82 (36 %) were discharged with a new handicap; TAG was observed in 142 (63 %). On univariate analysis, age, etiology, SE severity, and comorbidities were significantly related to outcome, while TAG was associated with neither outcome nor likelihood of SE control. Logistic regression for mortality identified etiology [odds ratio (OR) 18.8, 95 % confidence interval (CI) 4.3–82.8] and SE severity (STESS ≥3; OR 1.7, 95 % CI 1.2–2.4) as independent predictors, and for lack of return to baseline, again etiology (OR 7.4, 95 % CI 3.9–14.0) and STESS ≥3 (OR 1.7, 95 % CI 1.4–2.2). Similar results were found for the subgroup of 116 patients with generalized-convulsive SE. Receiver operator characteristic (ROC) analyses confirmed that TAG did not improve outcome prediction. This study of a large SE cohort suggests that treatment adherence to recommendations using current medications seems to play a negligible prognostic role (class III), confirming the importance of the biological background. Awaiting further treatment trials, it appears mandatory to apply resources towards identification of new therapeutic approaches.
Similar content being viewed by others
References
Commission on Epidemiology and Prognosis, International League Against Epilepsy (1993) Guidelines for epidemiologic studies on epilepsy. Epilepsia 34:592-596
Alvarez V, Januel JM, Burnand B, Rossetti AO (2012) Role of comorbidities in outcome prediction after status epilepticus. Epilepsia 53:e89–e92
Aranda A, Foucart G, Ducasse JL, Grolleau S, McGonigal A, Valton L (2010) Generalized-convulsive status epilepticus management in adults: a cohort study with evaluation of professional practice. Epilepsia 51:2159–2167
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383
Coeytaux A, Jallon P, Galobardes B, Morabia A (2000) Incidence of status epilepticus in French-speaking Switzerland: (EPISTAR). Neurology 55:693–697
DeLorenzo RJ, Hauser WA, Towne AR, Boggs JG, Pellock JM, Penberthy L, Garnett L, Fortner CA, Ko D (1996) A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 46:1029–1035
Drislane FW, Blum AS, Lopez MR, Gautam S, Schomer DL (2009) Duration of refractory status epilepticus and outcome: loss of prognostic utility after several hours. Epilepsia 50:1566–1571
Govoni V, Fallica E, Monetti VC, Guerzoni F, Faggioli R, Casetta I, Granieri E (2007) Incidence of Status Epilepticus in Southern Europe: a Population Study in the Health District of Ferrara, Italy. Eur Neurol 59:120–126
Holtkamp M (2011) Treatment strategies for refractory status epilepticus. Curr Opin Crit Care 17:94–100
Holtkamp M, Othman J, Buchheim K, Meierkord H (2005) Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry 76:534–539
Knake S, Rosenow F, Vescovi M, Oertel WH, Mueller HH, Wirbatz A, Katsarou N, Hamer HM (2001) Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia 42:714–718
Koubeissi M, Alshekhlee A (2007) In-hospital mortality of generalized-convulsive status epilepticus: a large US sample. Neurology 69:886–893
Leppert D, Stoeckli HR, Fuhr P (2005) Directives pour le traitement de l’état de mal épileptique. Schweizerische Aerztezeitung 86. www.saez.ch/status_epilepticus_f.pdf
Logroscino G, Hesdorffer DC, Cascino G, Annegers JF, Hauser WA (1997) Short-term mortality after a first episode of status epilepticus. Epilepsia 38:1344–1349
Lowenstein DH, Alldredge BK (1998) Status epilepticus. N Engl J Med 338:970–976
Lowenstein DH, Bleck T, Macdonald RL (1999) It’s time to revise the definition of status epilepticus. Epilepsia 40:120–122
Marchi N, Granata T, Freri E, Ciusani E, Ragona F, Puvenna V, Teng Q, Alexopolous A, Janigro D (2011) Efficacy of anti-inflammatory therapy in a model of acute seizures and in a population of pediatric drug resistant epileptics. PLoS ONE 6:e18200
Meierkord H, Boon P, Engelsen B, Gocke K, Shorvon S, Tinuper P, Holtkamp M (2010) EFNS guideline on the management of status epilepticus in adults. Eur J Neurol 17:348–355
Minicucci F, Muscas G, Perucca E, Capovilla G, Vigevano F, Tinuper P (2006) Treatment of status epilepticus in adults: guidelines of the Italian League against Epilepsy. Epilepsia 47(Suppl 5):9–15
Muayqil T, Rowe BH, Ahmed SN (2007) Treatment adherence and outcomes in the management of convulsive status epilepticus in the emergency room. Epileptic Disord 9:43–50
Neligan A, Shorvon SD (2011) Prognostic factors, morbidity and mortality in tonic-clonic status epilepticus: a review. Epilepsy Res 93:1–10
Novy J, Logroscino G, Rossetti AO (2010) Refractory status epilepticus: a prospective observational study. Epilepsia 51:251–256
Outin H, Blanc T, Vinatier I (2009) Emergency and intensive care unit management of status epilepticus in adult patients and children (new-born excluded). Societe de reanimation de langue francaise experts recommendations. Rev Neurol (Paris) 165:297–305
Rabinstein AA (2010) Management of status epilepticus in adults. Neurol Clin 28:853–862
Ravizza T, Balosso S, Vezzani A (2011) Inflammation and prevention of epileptogenesis. Neurosci Lett 497:223–230
Rossetti AO, Hurwitz S, Logroscino G, Bromfield EB (2006) Prognosis of status epilepticus: role of aetiology, age, and consciousness impairment at presentation. J Neurol Neurosurg Psychiatry 77:611–615
Rossetti AO, Logroscino G, Bromfield EB (2005) Refractory status epilepticus: effect of treatment aggressiveness on prognosis. Arch Neurol 62:1698–1702
Rossetti, AO, Logroscino G, Milligan TA, Michaelides C, Ruffieux C, Bromfield EB (2008) Status Epilepticus Severity Score (STESS): a tool to orient early treatment strategy. J Neurol 255:1561–1566
Rossetti AO, Lowenstein DH (2011) Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol 10:922–930
Rossetti AO, Novy J, Ruffieux C, Olivier P, Foletti GB, Hayoz D, Burnand B, Logroscino G (2009) Management and prognosis of status epilepticus according to hospital setting: a prospective study. Swiss Med Wkly 139:719–723
Scholtes FB, Renier WO, Meinardi H (1994) Generalized-convulsive status epilepticus: causes, therapy, and outcome in 346 patients. Epilepsia 35:1104–1112
Shneker BF, Fountain NB (2003) Assessment of acute morbidity and mortality in non-convulsive status epilepticus. Neurology 61:1066–1073
Shorvon S (2011) The treatment of status epilepticus. Curr Opin Neurol 24:165–170
Silbergleit R, Durkalski V, Lowenstein D, Conwit R, Pancioli A, Palesch Y, Barsan W (2012) Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 366:591–600
Towne AR, Pellock JM, Ko D, DeLorenzo RJ (1994) Determinants of mortality in status epilepticus. Epilepsia 35:27–34
van Rijckevorsel K, Boon P, Hauman H, Legros B, Ossemann M, Sadzot B, Schmedding E, van Zandijcke M (2006) Standards of care for non-convulsive status epilepticus: Belgian consensus recommendations. Acta Neurol Belg 106:117–124
Vignatelli L, Rinaldi R, Baldin E, Tinuper P, Michelucci R, Galeotti M, de Carolis P, D’Alessandro R (2008) Impact of treatment on the short-term prognosis of status epilepticus in two population-based cohorts. J Neurol 255:197–204
Wu YW, Shek DW, Garcia PA, Zhao S, Johnston SC (2002) Incidence and mortality of generalized-convulsive status epilepticus in California. Neurology 58:1070–1076
Conflicts of interest
A.O.R. received research grants from Pfizer, UCB, GSK, and Sandoz. All other authors do not have anything to disclose.
Ethical standard
This study has been approved by the appropriate ethics committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rossetti, A.O., Alvarez, V., Januel, JM. et al. Treatment deviating from guidelines does not influence status epilepticus prognosis. J Neurol 260, 421–428 (2013). https://doi.org/10.1007/s00415-012-6644-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-012-6644-x